Evidence map›Paper›PMID 30226605›Full record

ArticleOncology reports2018

STAT1‑HDAC4 signaling induces epithelial‑mesenchymal transition and sphere formation of cancer cells overexpressing the oncogene, CUG2.

Sirichat Kaowinn, Chutima Kaewpiboon, Sang Seok Koh, Oliver H Krämer, Young-Hwa Chung

Open access · hybridAbstract read
In one paragraph

Article in Oncology reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 39 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Differential molecular mechanistic behavior of HDACs in cancer progression.Medical oncology (Northwood, London, England) · 2022
    Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. InvestigatingFrontiers in genetics · 2022
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 3 countries.

Sirichat KaowinnBK21+, Department of Cogno‑Mechatronics Engineering, Pusan National University, Busan 46241, Republic of Korea.
Chutima KaewpiboonDepartment of Biology, Faculty of Science, Thaksin University, Phatthalung 93210, Thailand.
Sang Seok KohDepartment of Biological Sciences, Dong‑A University, Busan 49315, Republic of Korea.
Oliver H KrämerDepartment of Toxicology, University Medical Center Mainz, Mainz D‑55131, Germany.
Young-Hwa ChungBK21+, Department of Cogno‑Mechatronics Engineering, Pusan National University, Busan 46241, Republic of Korea.
Pusan National University · KRDong-A University · KRJohannes Gutenberg University Mainz · DEThaksin University · TH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Our previous studies have shown that the novel oncogene, cancer upregulated gene 2 (CUG2), activates STAT1, which is linked to anticancer drug resistance, induces epithelial‑mesenchymal transition (EMT) and cancer stem cell‑like phenotypes as determined by MTT, migration and sphere formation assays. We thus aimed to ascertain whether the activation of STAT1 by CUG2 is involved in these malignant phenotypes besides drug resistance. Here, we showed that STAT1 suppression decreased the expression of N‑cadherin and vimentin, biomarkers of EMT, which led to inhibition of the migration and invasion of human lung A549 cancer cells stably expressing CUG2, but did not recover E‑cadherin expression. STAT1 siRNA also diminished CUG2‑induced TGF‑β signaling, which is critical in EMT, and TGF‑β transcriptional activity. Conversely, inhibition of TGF‑β signaling reduced phosphorylation of STAT1, indicating a crosstalk between STAT1 and TGF‑β signaling. Furthermore, STAT1 silencing diminished sphere formation, which was supported by downregulation of stemness‑related factors such as Sox2, Oct4, and Nanog. Constitutive suppression of STAT1 also inhibited cell migration, invasion and sphere formation. As STAT1 acetylation counteracts STAT1 phosphorylation, acetylation of STAT1 by treatment with trichostatin A, an inhibitor of histone deacetylases (HDACs), reduced cell migration, invasion, and sphere formation. As HDAC4 is known to target STAT1, its role was investigated under CUG2 overexpression. HDAC4 suppression resulted in inhibition of cell migration, invasion, and sphere formation as HDAC4 silencing hindered TGF‑β signaling and decreased expression of Sox2 and Nanog. Taken together, we suggest that STAT1‑HDAC4 signaling induces malignant tumor features such as EMT and sphere formation in CUG2‑overexpressing cancer cells.

Indexed as

A549 CellsCell MovementChromosomal Proteins, Non-HistoneDrug Resistance, NeoplasmEpithelial-Mesenchymal TransitionGene Expression Regulation, NeoplasticHistone DeacetylasesHumansLung NeoplasmsNanog Homeobox ProteinRepressor ProteinsSignal TransductionSOXB1 Transcription FactorsSpheroids, CellularSTAT1 Transcription FactorTransforming Growth Factor betaCENPW protein, humanChromosomal Proteins, Non-HistoneHDAC4 protein, humanHistone DeacetylasesNanog Homeobox ProteinNANOG protein, humanRepressor ProteinsSOX2 protein, humanSOXB1 Transcription FactorsSTAT1 protein, humanSTAT1 Transcription FactorTransforming Growth Factor beta

Identifiers

PMID30226605
PMCPMC6151883
OpenAlexW2891100131

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.